MLL rearrangement
|
AML
|
MLL rearrangement
|
AML
|
palbociclib Sensitive: C2 – Inclusion Criteria
|
palbociclib Sensitive: C2 – Inclusion Criteria
|
MLL rearrangement
|
AML
|
MLL rearrangement
|
AML
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
MLL rearrangement
|
AML
|
MLL rearrangement
|
AML
|
abemaciclib Sensitive: C3 – Early Trials
|
abemaciclib Sensitive: C3 – Early Trials
|
MLL rearrangement
|
ALL
|
MLL rearrangement
|
ALL
|
blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials
|
blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials
|
MLL rearrangement
|
ALL
|
MLL rearrangement
|
ALL
|
inotuzumab ozogamicin Resistant: C3 – Early Trials
|
inotuzumab ozogamicin Resistant: C3 – Early Trials
|
MLL rearrangement
|
AML
|
MLL rearrangement
|
AML
|
KO-539 Sensitive: C3 – Early Trials
|
KO-539 Sensitive: C3 – Early Trials
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Resistant: C3 – Early Trials
|
blinatumomab Resistant: C3 – Early Trials
|
MLL rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
MLL rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|
MLL rearrangement
|
Leukemia
|
MLL rearrangement
|
Leukemia
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|